LENZ at a glance
LENZ Therapeutics, Inc. (LENZ, SEC CIK 1815776) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on October 28, 2026 and Form 4 insider filings as recently as November 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), LENZ Therapeutics, Inc. (LENZ) reported revenue of $19.1 million and a net loss of $82.1 million. Diluted EPS was -$2.85.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding LENZ Therapeutics, Inc. (LENZ) shares worth $34.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by RA CAPITAL MANAGEMENT, L.P. on October 29, 2026 of 451,998 shares at $3.36 per share.
- In the last 90 days, LENZ insiders reported 0 open-market purchases ($0) and 3 open-market sales ($9.1M) on Form 4, a net sale of $9.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $19.1M
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$9.1M
- 13F holders
- 26 funds
- $34.3M · +1 vs prior quarter
- Latest 8-K
- Oct 28, 2026
- Item 2.02 · Item 2.05 · Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Quarterly revenue $15.1M, versus $12.5M license revenue YoY, with $2.6M product sales
- Net loss $31.0M vs $16.7M YoY, with SG&A $35.8M vs $27.6M
- VIZZ product sales best-performing line: $2.6M from approximately 38,000 packs
- Cash, equivalents and marketable securities $197.3M; operating cash outflow $94.6M through nine months
- Strategic reorganization: approximately 75% headcount reduction, approximately $5M restructuring charges expected in fourth quarter 2026
Risk Factors
- New regulatory risk triggered by current administration: FDA staffing reductions and government shutdowns could delay reviews, inspections, and future approvals
- Most material commercial update: October 2026 reorganization prioritizing consumer marketing and reducing operating expenses
- Competitive risk: Ryzumvi approval in October 2026 adds another presbyopia treatment competitor
- Market-acceptance risk: VIZZ remains vulnerable to patient concerns about prescription burden and side effects versus reading glasses
- Financial risk: Net losses reached $104.4 million for nine months ended September 30, 2026, with accumulated deficit of $331.5 million
AI summary of the LENZ 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release announces LENZ’s financial results for the quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed earnings figures and management commentary
Item 2.05: Costs Associated with Exit or Disposal Activities
- Strategic reorganization prioritizes consumer marketing and sales-growth capital allocation
- Headcount reduced approximately 75%, leaving approximately 40 full-time employees
Item EX-99.1: Item EX-99.1
- Q3 product sales $2.6M, up 50% sequentially, with 38,000 paid prescriptions, supporting accelerating VIZZ adoption
- Telehealth generated over 50% of incremental prescriptions, expanding access beyond traditional eye-care channels
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CEO Evert Schimmelpennink departs December 1, 2026, resigning from the Board; transition is stated as non-disputed
- CFO Daniel Chevallard becomes Interim President and CEO while retaining CFO, principal financial and accounting officer responsibilities
Item 2.02: Results of Operations and Financial Condition
- Press release announces LENZ Therapeutics’ financial results for the quarter ended June 30, 2026
- Exhibit 99.1 contains the detailed quarterly results and management commentary
Item EX-99.1: Item EX-99.1
- Q2 revenue $5.5M, including $1.7M product sales and $3.8M license revenue
- VIZZ volume reached approximately 27,000 packs, up 9% sequentially, supporting early commercial traction
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Zach Scheiner resigned from the Board and all committees effective June 30, 2026
- Resignation unrelated to disputes over company operations, policies, or practices
AI summaries of LENZ 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LENZ
Don't miss the next LENZ filing
- Alerts as it files. A push when LENZ files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LENZ, by share count.
- Ask anything. An AI agent that reads every LENZ filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Chevallard Daniel R. | A | Oct 30, 2026 | 652,063 | - |
| RA CAPITAL MANAGEMENT, L.P. | Sell | Oct 29, 2026 | 451,998 | $3.36 |
| RA CAPITAL MANAGEMENT, L.P. | Sell | Oct 29, 2026 | 2,159,516 | $3.36 |
| RA CAPITAL MANAGEMENT, L.P. | Sell | Oct 29, 2026 | 107,170 | $3.36 |
| Guerard Frederic | A | Jun 15, 2026 | 22,100 | - |
| George Jeffrey P. | A | Jun 15, 2026 | 22,100 | - |
| Thunen Shelley B | A | Jun 15, 2026 | 22,100 | - |
| Drapkin Kimberlee C | A | Jun 15, 2026 | 22,100 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $0 | $19.1M |
| Operating Income | -$135.2M | -$58.6M | -$91.1M |
| Net Income | -$124.7M | -$49.8M | -$82.1M |
| Op. Margin | - | - | -477.5% |
| Net Margin | - | - | -430.3% |
| Balance Sheet | |||
| Total Assets | $188.5M | $215.3M | $305.9M |
| Equity | - | $204.1M | $284.3M |
| ROE | - | -24.4% | -28.9% |
| Per Share | |||
| EPS | - | $-2.34 | $-2.85 |
| Cash Flow | |||
| Operating CF | -$90.0M | -$59.4M | -$69.2M |
| CapEx | - | $468K | $827K |
Source: XBRL data in LENZ Therapeutics, Inc. (LENZ)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate LENZ share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $34.3M |
| Q2 2026 | 25 | $64.9M |
| Q1 2026 | 25 | $105.7M |
| Q4 2025 | 21 | $166.7M |
| Q3 2025 | 22 | $282.9M |
| Q2 2025 | 18 | $131.6M |
| Q1 2025 | 18 | $54.9M |
| Q4 2024 | 14 | $57.6M |
- BlackRock+1.15M (+50%)
- Two Sigma Investments+429.0K (+150%)
- Goldman Sachs Group+198.3K (+132%)
- Renaissance Technologies LLC+111.2K (+157%)
- State Street Corp+15.2K (+4%)
- Millennium Management−348.5K (-23%)
- Citadel Advisors LLC−267.9K (-74%)
- Bank of America Corp−215.9K (-85%)
- AQR Capital Management−101.9K (-45%)
- Morgan Stanley−63.6K (-13%)
- D.E. Shaw & Co+187.0K
- Ameriprise Financial+31.9K
- Raymond James Financial+22.7K
- FMR LLC (Fidelity)−3.56M
- Allstate−35.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 169 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LENZ filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 3, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| SC 13G | Jun 26, 2026 | - | - | |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 8-K | May 11, 2026 | - | Analysis | |
| 10-Q | May 11, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 27, 2026 | - | - | |
| SC 13G | Apr 8, 2026 | - | - | |
| 4 | Mar 30, 2026 | - | - | - |
| 4 | Mar 30, 2026 | - | - | - |
| 4 | Mar 30, 2026 | - | - | - |
| 8-K | Mar 24, 2026 | - | - | - |
| 10-K | Mar 24, 2026 | Dec 31, 2025 | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
LENZ SEC filings: frequently asked questions
Are LENZ insiders buying or selling?
In the last 90 days, LENZ Therapeutics, Inc. (LENZ) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $9.1 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold LENZ stock?
As of September 30, 2026, the largest LENZ Therapeutics, Inc. (LENZ) holders among the 13F filers tracked by SignalX were BlackRock ($13.2 million), Millennium Management ($4.5 million), Vanguard Capital Management LLC ($4.2 million), Two Sigma Investments ($2.7 million), State Street Corp ($1.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was LENZ's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), LENZ Therapeutics, Inc. (LENZ) reported revenue of $19.1 million and a net loss of $82.1 million. Diluted EPS was -$2.85. The figures come from the XBRL data in the 10-K.
What did LENZ report in its latest 8-K?
LENZ Therapeutics, Inc. (LENZ) filed an 8-K on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 2.05 (Costs Associated with Exit or Disposal Activities) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Press release announces LENZ’s financial results for the quarter ended September 30, 2026.
What are the latest LENZ SEC filings?
LENZ Therapeutics, Inc. (LENZ) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on October 28, 2026 and a Form 4 insider filing on November 3, 2026.
What is LENZ's SEC CIK number?
LENZ Therapeutics, Inc. (LENZ)'s SEC Central Index Key (CIK) is 1815776. EDGAR lists every LENZ filing under that number.
Ask anything about LENZ
The research agent reads LENZ's filings, financials, insider trades and 13F holders, then answers with sources.